Axsome Therapeutics AXSM Change In Fair Value Of Contingent Considerations
Change In Fair Value Of Contingent Considerations at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept axsm:ChangeInFairValueOfContingentConsiderations.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's change in fair value of contingent considerations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's change in fair value of contingent considerations?
- Axsome Therapeutics (AXSM) reported change in fair value of contingent considerations of $590K in Q1 2026.
- How has Axsome Therapeutics's change in fair value of contingent considerations changed year-over-year?
- Axsome Therapeutics's change in fair value of contingent considerations decreased by 61.0% year-over-year, from $1.51M to $590K.
- What is the long-term trend for Axsome Therapeutics's change in fair value of contingent considerations?
- Over 3 years (2022 to 2025), Axsome Therapeutics's change in fair value of contingent considerations has grown at a -9.2% compound annual growth rate (CAGR), from $3.3M to -$2.47M.
- What does change in fair value of contingent considerations mean?
- The change in the estimated cost of future acquisition-related payments.
- How do you interpret change in fair value of contingent considerations?
- A gain (reduction in liability) may suggest lower-than-expected performance, while a loss (increase in liability) may signal higher-than-expected progress.
- How does change in fair value of contingent considerations compare across companies?
- Specific to companies with active M&A strategies and milestone-based payment structures.